RSS   Newsletter   Contact   Advertise with us
Post Online Media

Intellia Therapeutics appoints two directors

Share on Twitter Share on LinkedIn
Staff Writer | Cambridge, Mass., USA | Wednesday July 26, 2017 5:33AM ET
Intellia TherapeuticsJuly 26, 2017, Cambridge, Mass., USA - Intellia Therapeutics, a gene editing company, announced the appointment of Moncef Slaoui and Frank Verwiel to its board of directors.
Please disable your ad blocker for POST to be able to enjoy our free content.
Moncef Slaoui recently retired as Chairman of Vaccines at GlaxoSmithKline (GSK), where he also served on the company’s executive team and board of directors for eleven years.

During his nearly 30-year career at GSK, Dr. Slaoui amassed significant expertise in drug discovery and development, business development, new product development and commercial organizations.

Dr. Slaoui led the global integration of Novartis’ vaccine unit into GSK. Dr. Slaoui was chairman of GSK’s global R&D organization for eight years, bringing improved productivity with more than 30 phase 3 programs, and re-organizing drug discovery to accommodate 38 focused discovery performance units in the company.

Additionally, he was responsible for GSK’s venture capital arm, SR One, and other venture capital partnerships.

Dr. Slaoui led the company’s bioelectronics R&D strategy, including the launch of Galvani Bioelectronics, a company where he remains Chairman of the board of directors.

Dr. Slaoui has authored more than 100 scientific papers and presentations and served on the board of directors for the Pharmaceutical Research and Manufacturers of America’s Foundation, the Biotechnology Innovation Organization’s board of directors, and was a member of the National Institutes of Health’s Advisory Committee until 2016.

Currently, he is a member of the Advisory Board for the Qatar Foundation.

Dr. Slaoui received his Ph.D. in Molecular Biology and Immunology from the Université libre de Bruxelles Belgium and completed post-doctoral studies at Harvard Medical School and Tufts University of Medicine in Boston.

Frank Verwiel brings more than 25 years of strategic, operational and international expertise in the biotechnology and pharmaceutical industries and over a decade of industry board experience.

Dr. Verwiel possesses significant biotech and pharmaceutical experience, having been the president and CEO of Aptalis Pharma Inc., prior to its acquisition in 2014 by Forest Laboratories.

Dr. Verwiel also was a vice president at Merck & Co., where he led the global hypertension franchise.

He also served as the general manager of Merck Sharpe Dohme’s operations in the Netherlands.

He held numerous leadership positions in the commercial organization at Servier Laboratories.

Dr. Verwiel currently serves as chairman of the board of directors of ObsEva SA, a biopharmaceutical company focused on women’s reproductive health.

He holds membership and committee chair positions on the boards of AveXis, Inc., Achillion Pharmaceuticals, Inc. and Bavarian Nordic A/S.

Previously, he served on the board of directors of Intermune, until its acquisition by Roche in 2014, and the Biotechnology Innovation Organization.

Dr. Verwiel received a doctorate in medicine from Erasmus University in Rotterdam, Netherlands. He received a Masters of Business Administration from the Institut Européen d'Administration des Affaires (INSEAD) in Fontainebleau, France.

 

 LATEST MOVES FROM Massachusetts 


POST Online Media Contact

 More inside POST